Keywords: Probes & Targets, Hyperpolarized MR (Non-Gas)
Motivation: Molecular imaging is a promising methodology for diagnosing cancer and monitoring treatments by noninvasively visualizing the alternations of cancer metabolisms.
Goal(s): A framework for developing novel dissolution Dynamic Nuclear Polarization(dDNP) probes is needed to overcome their limited availabilities for in vivo and clinical applications.
Approach: dDNP-metabolic MRI successfully monitors therapeutic responses in spatiotemporal enzymatic activities particularly at earlier stages before the volumetric changes can be observed.
Results: In this presentation, we will demonstrate a model case for a rationally designed novel dDNP probe, aminopeptidase-N(CD13), which allows us to detect heterogenetic treatment responses with an anti-angiogenic/antitumor drug, sunitinib, at the earlier stages in tumors.
Impact: This work exhibits a framework that a rationally designed hyperpolarized MR probe targeted to a highly-selective enzymatic activity, aminopeptidase-N, leads to monitor early therapeutic responses on cancer tissues in vivo and to observe tumor heterogeneity in their treatment responses non-invasively.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords